{"id":"levetiracetam-iv","safety":{"commonSideEffects":[{"rate":"15-30","effect":"Somnolence"},{"rate":"10-15","effect":"Asthenia/Fatigue"},{"rate":"10-15","effect":"Dizziness"},{"rate":"5-10","effect":"Headache"},{"rate":"5-15","effect":"Behavioral/mood changes (irritability, aggression)"},{"rate":"5-10","effect":"Ataxia/Coordination problems"},{"rate":"5-10","effect":"Infection"}]},"_chembl":{"chemblId":"CHEMBL1286","moleculeType":"Small molecule","molecularWeight":"170.21"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levetiracetam is a pyrrolidone derivative that binds to the synaptic vesicle protein SV2A in the brain, which regulates the release of neurotransmitters involved in seizure propagation. Unlike traditional anticonvulsants, it does not directly affect sodium or calcium channels, and its exact mechanism remains partially unclear, though SV2A binding is considered the primary molecular interaction. This unique mechanism makes it effective across multiple seizure types with a favorable safety profile.","oneSentence":"Levetiracetam reduces neuronal excitability and seizure activity through binding to synaptic vesicle protein SV2A, modulating neurotransmitter release.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:42.010Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy (adjunctive therapy for partial-onset seizures)"},{"name":"Epilepsy (adjunctive therapy for myoclonic seizures)"},{"name":"Epilepsy (adjunctive therapy for primary generalized tonic-clonic seizures)"}]},"trialDetails":[{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT06345495","phase":"PHASE2","title":"High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-10-01","conditions":"Splenomegaly, Myelofibrosis","enrollment":30},{"nctId":"NCT07401433","phase":"NA","title":"Levetiracetam Versus Phenobarbitone for the Treatment of Neonatal Seizures in a Tertiary Care Hospital.","status":"COMPLETED","sponsor":"Hayat Abad Medical Complex, Peshawar","startDate":"2024-04-08","conditions":"Neonatal Seizures","enrollment":260},{"nctId":"NCT01150331","phase":"PHASE3","title":"Study of Antiepileptic Drug in Generalised Convulsive Status Epilepticus","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2009-07","conditions":"Status; Epilepticus, Tonic-clonic","enrollment":203},{"nctId":"NCT07284498","phase":"PHASE4","title":"Treatment of Seizures in Neonate With HIE","status":"NOT_YET_RECRUITING","sponsor":"Mansoura University","startDate":"2026-01-01","conditions":"Neonatal Seizures, HIE - Hypoxic - Ischemic Encephalopathy","enrollment":66},{"nctId":"NCT01857934","phase":"PHASE2","title":"Therapy for Children With Advanced Stage Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-07-05","conditions":"Neuroblastoma","enrollment":153},{"nctId":"NCT05610085","phase":"PHASE2","title":"A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2023-03-24","conditions":"Neonatal Seizure, Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy","enrollment":133},{"nctId":"NCT02631759","phase":"PHASE3","title":"Prevention of Epileptic Seizures in Acute intraCerebral Haemorrhage","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2016-10","conditions":"Acute intraCerebral Haemorrhage","enrollment":50},{"nctId":"NCT07072624","phase":"PHASE4","title":"Early Post-Traumatic Seizures Prevention Trial (E-PTS Trial)","status":"RECRUITING","sponsor":"All India Institute of Medical Sciences, Jodhpur","startDate":"2025-07-23","conditions":"Seizures, Traumatic Brain Injuries, Traumatic Brain Injury (TBI) Patients","enrollment":1260},{"nctId":"NCT07098728","phase":"NA","title":"Levetiracetam Versus Phenobarbital in Benzodiazepines Unresponsive Paediatric Prolonged Seizures","status":"RECRUITING","sponsor":"Ministry of Health and Sports, Myanmar","startDate":"2025-07-22","conditions":"Seizure","enrollment":180},{"nctId":"NCT05735717","phase":"PHASE2","title":"MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-05-11","conditions":"Hematologic Malignancy, Acute Leukemia, Remission","enrollment":70},{"nctId":"NCT01666080","phase":"NA","title":"Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2012-08","conditions":"Hematologic Disorders, Hemoglobinopathies, Immunodeficiencies","enrollment":30},{"nctId":"NCT06773364","phase":"PHASE3","title":"Early Initiated Ambulance-delivered Levetiracetam and Headposition in Hyper-acute Stroke Trial","status":"RECRUITING","sponsor":"Shanghai East Hospital","startDate":"2025-04-30","conditions":"Suspected Stroke","enrollment":2423},{"nctId":"NCT06851078","phase":"PHASE3","title":"Evaluation of Early Administration of Levetiracetam in the Prevention and Treatment Encephalopathy in Septic Shock: Randomized, Double-blind, Placebo-controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-03-15","conditions":"Septic Shock","enrollment":280},{"nctId":"NCT02348216","phase":"PHASE1, PHASE2","title":"Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2015-04-21","conditions":"Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL)","enrollment":307},{"nctId":"NCT03325439","phase":"PHASE3","title":"A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures","status":"TERMINATED","sponsor":"UCB Biopharma SRL","startDate":"2019-05-07","conditions":"Electroencephalographic Neonatal Seizures","enrollment":9},{"nctId":"NCT01505569","phase":"NA","title":"Auto Transplant for High Risk or Relapsed Solid or CNS Tumors","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2011-10-20","conditions":"Ewing's Family Tumors, Renal Tumors, Hepatoblastoma","enrollment":44},{"nctId":"NCT02056236","phase":"NA","title":"TELSTAR: Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation","status":"COMPLETED","sponsor":"University of Twente","startDate":"2014-04","conditions":"Cardiac Arrest, Anoxic Encephalopathy, Status Epilepticus","enrollment":172},{"nctId":"NCT00584025","phase":"PHASE4","title":"Keppra IV for the Treatment of Motor Fluctuations in Parkinson's Disease","status":"WITHDRAWN","sponsor":"University of South Florida","startDate":"2007-12","conditions":"Parkinson's Disease","enrollment":""},{"nctId":"NCT01239212","phase":"PHASE1, PHASE2","title":"Dosing of Levetiracetam (Keppra) in Neonates","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2010-09","conditions":"Seizures","enrollment":7},{"nctId":"NCT01685411","phase":"NA","title":"Busulfan and Cyclophosphamide Followed By ALLO BMT","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2013-01","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":5},{"nctId":"NCT00160654","phase":"PHASE4","title":"Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2003-11-24","conditions":"Epilepsy, Partial","enrollment":251},{"nctId":"NCT01554683","phase":"NA","title":"Seizure Activity in Alzheimer's Disease","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2012-02","conditions":"Alzheimer's Disease, Seizures","enrollment":12},{"nctId":"NCT00884052","phase":"PHASE1, PHASE2","title":"Pharmacokinetic and Safety Trial of Intravenous Levetiracetam in the Treatment of Neonatal Seizures","status":"COMPLETED","sponsor":"Richard H. Haas","startDate":"2007-04","conditions":"Seizures, Disorder of Fetus or Newborn","enrollment":18},{"nctId":"NCT00489281","phase":"PHASE2","title":"Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2008-06-23","conditions":"Sickle Cell Disease","enrollment":43},{"nctId":"NCT03580707","phase":"PHASE2, PHASE3","title":"Does BRV Have Faster Onset Time & Greater Effect Than LEV in Epilepsy Pts Using PPR Pharmacodynamic Efficacy Endpoint","status":"COMPLETED","sponsor":"Rosenfeld, William E., M.D.","startDate":"2018-06-01","conditions":"Photosensitive Epilepsy","enrollment":16},{"nctId":"NCT00404248","phase":"PHASE1, PHASE2","title":"Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2007-01","conditions":"Brain and Central Nervous System Tumors","enrollment":35},{"nctId":"NCT00627133","phase":"PHASE2","title":"Efficacy of Keppra in Acute Alcohol Related Seizure Control--A Pilot Study","status":"WITHDRAWN","sponsor":"Medical University of South Carolina","startDate":"2008-02","conditions":"Seizure, Alcohol Related","enrollment":""},{"nctId":"NCT01464359","phase":"PHASE2","title":"T-Cell Depleted Double UCB for Refractory AML","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2011-10","conditions":"Acute Myelogenous Leukemia, Refractory Acute Myelogenous Leukemia","enrollment":3},{"nctId":"NCT01935908","phase":"PHASE4","title":"Seizure Prophylaxis With Levetiracetam in Aneurysmal Subarachnoid Hemorrhage - Pilot Study","status":"WITHDRAWN","sponsor":"Vanderbilt University Medical Center","startDate":"2013-05","conditions":"Subarachnoid Hemorrhage, Seizures","enrollment":""},{"nctId":"NCT02602860","phase":"PHASE1","title":"A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2015-11","conditions":"Healthy Volunteers","enrollment":13},{"nctId":"NCT01229735","phase":"PHASE4","title":"Levetiracetam Versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures","status":"COMPLETED","sponsor":"UCB Korea Co., Ltd.","startDate":"2010-11","conditions":"Epilepsy","enrollment":343},{"nctId":"NCT02472392","phase":"PHASE1","title":"Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma","status":"COMPLETED","sponsor":"University of Louisville","startDate":"2013-04","conditions":"EWINGS SARCOMA","enrollment":10},{"nctId":"NCT03107507","phase":"PHASE4","title":"Efficacy of Levetiracetam in Control of Neonatal Seizures Guided by an EEG","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2017-03-25","conditions":"Neonatal Seizures","enrollment":40},{"nctId":"NCT02920060","phase":"PHASE2","title":"Levetiracetam Versus Sodium Valproate in Children With Refractory Generalized Convulsive Status Epilepticus","status":"COMPLETED","sponsor":"Banaras Hindu University","startDate":"2015-01","conditions":"Grand Mal Status Epilepticus","enrollment":80},{"nctId":"NCT00505934","phase":"PHASE2","title":"Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2008-05","conditions":"Epilepsy","enrollment":19},{"nctId":"NCT00618436","phase":"PHASE4","title":"Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure Prevention","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2007-08","conditions":"Traumatic Brain Injury, Subarachnoid Hemorrhage","enrollment":52},{"nctId":"NCT00510783","phase":"PHASE4","title":"IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures","status":"COMPLETED","sponsor":"Emory University","startDate":"2007-07","conditions":"Tonic-clonic Seizure","enrollment":158},{"nctId":"NCT00631150","phase":"PHASE4","title":"A Phase IV-Pharmacovigilance Study of Keppra Greece - S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2003-03","conditions":"Epilepsy","enrollment":35},{"nctId":"NCT00630357","phase":"PHASE4","title":"Trial to Evaluate the Safety and Efficacy of Keppra After Conversion to Mono-therapy in Subjects With Partial Epilepsy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2003-03","conditions":"Epilepsy","enrollment":14},{"nctId":"NCT01475656","phase":"","title":"Efficacy of Keppra for Neonatal Seizures","status":"TERMINATED","sponsor":"Stephanie Merhar, MD","startDate":"2011-11","conditions":"Neonatal Seizures","enrollment":2},{"nctId":"NCT01725009","phase":"PHASE1","title":"Multiple-dose Study of Levetiracetam Injection in Japanese and Caucasian Healthy Males","status":"COMPLETED","sponsor":"UCB Japan Co. Ltd.","startDate":"2012-10","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT01407523","phase":"PHASE2","title":"An Open Label Study of L059 Intravenous (IV) in Japanese Epilepsy Subjects With Partial Onset Seizures","status":"COMPLETED","sponsor":"UCB Japan Co. Ltd.","startDate":"2011-07","conditions":"Epilepsy, Partial Onset Seizures","enrollment":16},{"nctId":"NCT00438451","phase":"PHASE4","title":"Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs","status":"COMPLETED","sponsor":"Johannes Gutenberg University Mainz","startDate":"2007-01","conditions":"Focal Epilepsy","enrollment":361},{"nctId":"NCT00465244","phase":"PHASE2, PHASE3","title":"Seizure Therapy With Intravenous Levetiracetam and Lorazepam","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2008-01","conditions":"Seizures","enrollment":""},{"nctId":"NCT01618877","phase":"PHASE1","title":"A Randomized, Double-blind, Pharmacokinetics Study to Assess Safety, Tolerability of Levetiracetam 45 Minutes Intravenous Infusion During 4 Days of Bid Dosing in Chinese Healthy Volunteers","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2012-05","conditions":"Human Volunteers","enrollment":24},{"nctId":"NCT01618903","phase":"PHASE1","title":"An Open-label, Bioequivalence Study to Evaluate LEV Administered as a 45-min Intravenous Infusion and Same Dosage LEV Oral Tablet in Chinese","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2012-05","conditions":"Human Volunteers","enrollment":24},{"nctId":"NCT01394224","phase":"PHASE1","title":"Bioequivalence Study of Levetiracetam Tablet and Intravenous Infusion in Healthy Japanese Subjects","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2011-06","conditions":"Healthy Volunteers","enrollment":25},{"nctId":"NCT00535392","phase":"PHASE2","title":"Open-label Study of Levetiracetam Intravenous Infusion in Children (4-16 Years Old) With Epilepsy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2007-09","conditions":"Epilepsy","enrollment":33},{"nctId":"NCT01261416","phase":"","title":"Pharmacokinetics of Levetiracetam (Keppra) in Neonates","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2008-10","conditions":"Seizures, Epilepsy","enrollment":18},{"nctId":"NCT00146471","phase":"PHASE3","title":"Efficacy and Safety of Levetiracetam in the Inpatient Treatment of Alcohol Withdrawal Syndrome","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2006-01","conditions":"Alcohol Withdrawal Syndrome","enrollment":120},{"nctId":"NCT00307450","phase":"PHASE4","title":"Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"Technische Universität Dresden","startDate":"2006-03","conditions":"Parkinson's Disease","enrollment":34}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":216,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Levetiracetam IV","genericName":"Levetiracetam IV","companyName":"Ministry of Health and Sports, Myanmar","companyId":"ministry-of-health-and-sports-myanmar","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levetiracetam reduces neuronal excitability and seizure activity through binding to synaptic vesicle protein SV2A, modulating neurotransmitter release. Used for Epilepsy (adjunctive therapy for partial-onset seizures), Epilepsy (adjunctive therapy for myoclonic seizures), Epilepsy (adjunctive therapy for primary generalized tonic-clonic seizures).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}